



Market Announcement

12 October 2018

CardieX Limited (ASX: CDX) – Trading Halt

Description

The securities of CardieX Limited ('CDX') will be placed in trading halt at the request of CDX, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Tuesday, 16 October 2018 or when the announcement is released to the market.

Issued by

Clare Porta

Adviser, Listings Compliance (Sydney)



12 October 2018

Ms Clare Porter

By Email

To: Clare.Porta@asx.com.au; tradinghaltssydney@asx.com.au

Dear Sir,

**RE: Request for Trading Halt on Securities of CardieX Limited
(ASX: CDX)**

Pursuant to Listing Rule 17.1, pending an announcement regarding a material transaction that the Company is in the process of finalising binding legal documentation, CDX formally applies for a trading halt to be put in place pre-commencement of trade today.

That trading halt is requested to be in place until commencement of trade 16 October 2018 or when that announcement is released to the market.

CDX is not aware of any reason why the Company's request for a trading halt should not be granted.

Yours sincerely,

CARDIEX LIMITED

A handwritten signature in blue ink, appearing to read "Jarrod White", written over the company name.

**JARROD WHITE
CHIEF FINANCIAL OFFICER | COMPANY SECRETARY**

For more information please contact:

Chief Financial Officer
Jarrod White
Ph: +61 8296 0000
jwhite@cardiex.com

Investor Relations
Peter Taylor
Ph: +61 412 036 231
peter@nwrcommunications.com.au

About CardieX

CardieX is a Sydney based global health technology company focused on developing solutions for large-scale population health disorders. The Company's "AtCor Medical" division develops and markets products for the early detection of target organ damage and the management of cardiovascular and renal disease.